DOVA - DOVA Stock Climbs 38% on Buyout News from Swedish Drugmaker

DOVA stock climbed Monday after Dova Pharmaceuticals (NASDAQ:DOVA) announced a buyout offer from a Swedish drugmaker, Orphan Biovitrum.

Here’s everything we know about the deal, from start to finish.

On September 30, Dova Pharmaceuticals said Swedish Orphan Biovitrum will purchase the company for $27.50 a share in cash. If, however, the FDA approves Dova’s primary candidate Doptelet, which is used in the treatment of chemotherapy-induced thrombocytopenia, Orphan Biovitrum (OM: SOBI) will buy the company for an additional $1.50 a share.

“We are extremely pleased to ...